Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 132,276

Document Document Title
WO/2019/013616A1
The invention provides for an enteral nutritional composition comprising (a) a lipid fraction, (b) a digestible carbohydrate fraction and (c) a protein fraction, wherein the lipid fraction comprises therapeutically effective amounts of (...  
WO/2019/013244A1
Provided is a novel method for producing a (2S)-2-[(1H-pyrazol-1-yl)methyl]-1,3-oxazinane derivative. More specifically, a method for producing a (2S)-2-[(1H-pyrazol-1-yl)methyl]-1,3-oxazinane derivative represented by formula (1) is pro...  
WO/2019/014457A1
The present invention includes a method for identifying an Alzheimer's disease (AD) patient prior to reaching clinical disease classification, comprising: obtaining a dataset associated with a blood, serum, or plasma sample from the pati...  
WO/2019/013703A1
The present invention relates to bicydic alkyne compounds of Formula (I) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNKIa, and MNKIb. The present invention further relates to pharmaceutical compositions co...  
WO/2019/012033A1
The present invention relates to deuterated fezolinetant (R)-(4-fluorophenyl)-(8-methyl- 3-(3methyl-d3)-1,2,4-thiadiazol-5-yl)-5,6-dihydio-[1,2,4]tri zolo[4,3-a]pyrazin-7(8H)- yl)methanone, or a pharmaceutically acceptable salt or solvat...  
WO/2019/011954A1
The aim of the invention is to allow the best possible bioavailability of curcumin, boswellia, and xanthohumol. According to the invention, this is achieved by providing a solubilisate containing curcumin with a content of less than or e...  
WO/2019/011767A1
The present invention relates to 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.  
WO/2019/014547A1
The present invention includes compositions and methods for treating a subject afflicted with a neurodegenerative disorder or disease by determining that the subject is in need of treatment for the neurodegenerative disorder or disease; ...  
WO/2019/011664A1
The invention relates to a composition comprising a scent, characterized in that a cannabis smoker when exposed to the scent experience one or more of:a response in the cannabis smoker that in at least one parameter corresponds to a phys...  
WO/2019/011350A1
Disclosed are an FLZ crystal G form, a preparation method, and a composition and the use thereof, in particular the crystal G form of an FLZ compound (I) (chemical name: trans-2-(2,5-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)- N-(4-h...  
WO/2019/014631A1
Water-soluble cannabinoid compositions are described herein. The composition may include a cannabinoid mixture, e.g., purified from a cannabis extract, and one or more water soluble agents, such as a complex carbohydrate. Methods of prep...  
WO/2019/012109A1
The present invention relates to probenecid or a pharmaceutical acceptable salt thereof for use in the treatment of a neurological disorder in a subject in need thereof, wherein administration of probenecid or a pharmaceutical acceptable...  
WO/2019/010583A1
Methods and uses for treating a neurodevelopmental disorder such as Rett Syndrome are provided. In particular, the present disclosure provides methods and uses relating to treating a subject with the neurodevelopmental disorder by target...  
WO/2019/011770A1
The present invention relates to 2-oxo-1,3-oxazolidinyl imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.  
WO/2019/014418A1
The present disclosure provides, in some embodiments, methods for treating a neurodegenerative disease in a subject using a histone deacetylase 2 (HDAC2)/Sp3 inhibitor, which may be a peptide inhibitor comprising the carboxyl-terminus of...  
WO/2019/011955A2
In order to make available the health-promoting and healing properties of curcumin to the human or animal organism, and in combination with at least one other active substance, the invention provides a solubilisate consisting of or conta...  
WO/2019/014305A1
Substituted benzoxazole and benzofuran chemical entities of Formula (I): wherein, V, W, X, Y, Z, and m have any of the values described herein and compositions comprising such chemical entities; processes for making them; and their use i...  
WO/2019/013635A1
The invention provides for an enteral nutritional composition comprising (a) a lipid fraction, (b) a digestible carbohydrate fraction and (c) a protein fraction, wherein the lipid fraction comprises therapeutically effective amounts of (...  
WO/2019/012093A1
The present invention relates to novel compounds that inhibit LRRK2 kinase activity, to processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases associated with or ch...  
WO/2019/014153A1
The present disclosure provides a method of modulating protein expression from a Mena-ribonucleoprotein (RNP) complex, the method comprising administering to a subject an agent that: (a) inhibits protein expression by inhibiting Mena tra...  
WO/2019/012137A1
The invention relates to a combination for use in the treatment of multiple sclerosis of propionic acid and/or butyric acid and/or their physiologically acceptable salts or esters as enhancers on the one hand and of fingolimod on the oth...  
WO/2019/012173A1
The present invention relates to piperidine derivatives as inhibitors of the PDE8A enzyme. Therefore, said compounds can be used in the production of a drug for the treatment and/or prevention of diseases involving PDE8A, such as neurode...  
WO/2019/011414A1
The aim of the invention is to allow the best possible bioavailability of curcumin and boswellia. According to the invention, this is achieved by providing a solubilisate which contains curcumin with a content of less than or equal to 10...  
WO/2019/014427A1
Disclosed herein are cyclopropylpiperidme compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (niAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions compr...  
WO/2019/012284A1
The present invention relates to pyrrolopyrimidine compounds according to Formula (I) and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological d...  
WO/2019/013615A1
The invention pertains to a composition for use in producing white matter, producing myelin and/or reducing brain lesion size in a mammal suffering from or recovering from traumatic brain injury, comprising enterally administering to the...  
WO/2019/012063A1
The invention provides novel compounds having the general formula (I): (I) wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.  
WO/2019/012267A1
The present invention relates to the use of cannabinoids in the treatment of a neurodegenerative disease or disorder. In particular the cannabinoids cannabidiolic acid (CBDA) and cannabidivarin (CBDV) were able to produce neuroprotective...  
WO/2019/012108A1
The invention relates to an agent for use in the prophylactic and/or supporting therapeutic treatment of Parkinson's disease, containing a physiologically effective amount of propionic acid and/or butyric acid and/or the physiologically ...  
WO/2019/012042A1
The present invention relates to a compound of formula (I) below: formula (I) or a pharmaceutically acceptable salt thereof, in which R is an alkyl group comprising 1 to 10 carbon atoms. The invention also relates to the use thereof as a...  
WO/2019/011170A1
Provided are: an oxadiazole derivative as shown in formula (1), or salts, esters, stereoisomers, tautomers, polymorphs, solvates, hydrates, metabolites or prodrugs thereof, or a mixture of said substances; a pharmaceutical composition co...  
WO/2019/011290A1
Pharmaceutical compositions of ramelteon for use in the treatment of insomnia or jet lag by transmucosal administration. More specifically, the pharmaceutical composition is formulated into nasal spray or nasal drop for intranasal admini...  
WO/2019/013141A1
Provided are: a restraining type antisense oligonucleotide targeting TDP-43 mRNA, said antisense oligonucleotide containing a nucleotide sequence complementary to a sequence consisting of at least 10 consecutive nucleotides in a nucleoti...  
WO/2019/012047A1
The present invention relates to a transdermal therapeutic system for cutaneous administration of fampridine comprising an active ingredient-impermeable backing layer, a pressure-sensitive adhesive reservoir layer and optionally a detach...  
WO/2019/012150A1
The invention relates to organic cation transporters (OCTs) inhibitors of Formula (A), as well as their pharmaceutically acceptable tautomers, salts or solvates. The invention is also directed to pharmaceutical compositions comprising su...  
WO/2019/014304A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...  
WO/2019/011279A1
The present disclosure relates to an N-(substituted naphthyl-ethyl) substituted amide compound and uses thereof serving as a melatonin receptor agonist and 5-HT2c receptor antagonist, and specifically relates to the compound of formula (...  
WO/2019/013181A1
Provided is a degradation agent which uses an autophagic mechanism of damaged mitochondria, the degradation agent comprising: a compound that has a ligand capable of binding to or accumulating in mitochondria and that has a substituent g...  
WO/2019/011349A1
Disclosed are an FLZ crystal B form, a preparation method, and a composition and the use thereof, in particular the crystal B form of an FLZ compound (I) (chemical name: trans-2-(2,5-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)- N-(4-h...  
WO/2019/008029A1
The present invention relates to compounds of formula (I): wherein Q is O or S, R1 is a 6-membered heteroaryl group containing at least one nitrogen atom in the 6-membered ring structure, wherein R1 may optionally be substituted, and R2 ...  
WO/2019/008507A1
The invention is directed to substituted azetidine derivatives. Specifically, the invention is directed to compounds according Formula I: (I) wherein C, D, L1,L2,L3,R1, R2, R4, R5, R6, z2, z4, z5, and z6are as defined herein; and salts t...  
WO/2019/009298A1
According to the present invention, a nucleic acid medicine, which has a higher effect of inhibiting α-synuclein expression and sustains this effect for a longer period of time, can be provided. The oligonucleotide according to the pres...  
WO/2019/007443A1
Disclosed are a dezocine analogue ester-containing sustained-release suspension and a preparation method therefor. An injectable oleaginous additive and an excipient are selected to act as a pharmaceutical sustained-release reservoir, an...  
WO/2019/008034A1
The present invention relates to crystalline forms of N-[1-(5-cyano-pyridin-2-ylmethyl)-1H- pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-a cetamide, pharmaceutical compositions comprising said crystalline forms and their us...  
WO/2019/008393A1
This invention relates to a new use of compounds that are angiotensin II (Ang II) receptor agonists, more particularly agonists of the Ang II type 2 receptor (the AT2 receptor), and especially agonists that bind selectively to the AT2 re...  
WO/2019/008506A1
The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein X, a, b, C, D, L2, L3, Y1, Y2, R2, R4, R5, R6, z2, z4, z5, and z6 are as defi...  
WO/2019/007441A1
Disclosed are a sustained release suspension containing dezocine analogue ester and a preparation method therefor. According to the present invention, an injectable oily auxiliary material which may pharmaceutically serve as a sustained-...  
WO/2019/008144A1
The present invention relates to the use of a liquid aqueous solution of edaravone in the treatment of an oxidative stress-mediated neurodegenerative disorder in a human patient, said treatment comprising at least once daily oral adminis...  
WO/2019/010254A1
Described herein are methods and compositions for the use of treating damage induced by SD. Aspects of the invention relate to administering to a subject in need thereof an agent that reduces reactive oxygen species. In some embodiments,...  
WO/2019/008152A1
The present invention provides novel compounds of formula (I) that are useful as inhibitors of the PD-l/PD-Ll protein/protein interaction. The compounds may be used in the treatment of cancer, infectious diseases and neurodegenerative di...  

Matches 1 - 50 out of 132,276